%0 Journal Article
%A Karunamuni, Roshan A
%A Huynh-Le, Minh-Phuong
%A Fan, Chun C
%A Thompson, Wesley
%A Eeles, Rosalind A
%A Kote-Jarai, Zsofia
%A Muir, Kenneth
%A Lophatananon, Artitaya
%A Schleutker, Johanna
%A Pashayan, Nora
%A Batra, Jyotsna
%A Grönberg, Henrik
%A Walsh, Eleanor I
%A Turner, Emma L
%A Lane, Athene
%A Martin, Richard M
%A Neal, David E
%A Donovan, Jenny L
%A Hamdy, Freddie C
%A Nordestgaard, Børge G
%A Tangen, Catherine M
%A MacInnis, Robert J
%A Wolk, Alicja
%A Albanes, Demetrius
%A Haiman, Christopher A
%A Travis, Ruth C
%A Stanford, Janet L
%A Mucci, Lorelei A
%A West, Catharine M L
%A Nielsen, Sune F
%A Kibel, Adam S
%A Wiklund, Fredrik
%A Cussenot, Olivier
%A Berndt, Sonja I
%A Koutros, Stella
%A Sørensen, Karina Dalsgaard
%A Cybulski, Cezary
%A Grindedal, Eli Marie
%A Park, Jong Y
%A Ingles, Sue A
%A Maier, Christiane
%A Hamilton, Robert J
%A Rosenstein, Barry S
%A Vega, Ana
%A Committee, IMPACT Study Steering
%A Kogevinas, Manolis
%A Penney, Kathryn L
%A Teixeira, Manuel R
%A Brenner, Hermann
%A John, Esther M
%A Kaneva, Radka
%A Logothetis, Christopher J
%A Neuhausen, Susan L
%A Razack, Azad
%A Newcomb, Lisa F
%A Gamulin, Marija
%A Usmani, Nawaid
%A Claessens, Frank
%A Gago-Dominguez, Manuela
%A Townsend, Paul A
%A Roobol, Monique J
%A Zheng, Wei
%A Mills, Ian G
%A Andreassen, Ole A
%A Dale, Anders M
%A Seibert, Tyler M
%T Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer.
%J Prostate cancer and prostatic diseases
%V 24
%N 2
%@ 1476-5608
%C Basingstoke
%I Stockton Press
%M DKFZ-2021-01162
%P 532 - 541
%D 2021
%X Polygenic hazard scores (PHS) can identify individuals with increased risk of prostate cancer. We estimated the benefit of additional SNPs on performance of a previously validated PHS (PHS46).180 SNPs, shown to be previously associated with prostate cancer, were used to develop a PHS model in men with European ancestry. A machine-learning approach, LASSO-regularized Cox regression, was used to select SNPs and to estimate their coefficients in the training set (75,596 men). Performance of the resulting model was evaluated in the testing/validation set (6,411 men) with two metrics: (1) hazard ratios (HRs) and (2) positive predictive value (PPV) of prostate-specific antigen (PSA) testing. HRs were estimated between individuals with PHS in the top 5
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:33420416
%R 10.1038/s41391-020-00311-2
%U https://inrepo02.dkfz.de/record/168960